Agradecimentos: Open access publishing facilitated by The University of Sydney, as part of the Wiley - The University of Sydney agreement via the Council of Australian University Librarians. Prof. Karen Canfell reports she is co-PI, and A/Prof Michael Caruana reports that he is an investigator, of an investigator-initiated trial of cervical screening, "Compass," run by the Australian Centre for Prevention of Cervical Cancer (ACPCC), which is a government-funded not-for-profit charity. The ACPCC has received equipment and a funding contribution from Roche Molecular Diagnostics. Prof. Canfell is also co-PI on a major implementation program "Elimination of Cervical Cancer in the Western Pacific" which receives support from the Minderoo Foundation and equipment donations from Cepheid Inc. Dr Fabio Ynoe de Moraes reports a previous consulting fee from Câncer em Foco; he also reports honoraria from AstraZeneca and IASLC, both outside of the current work. Dr Lisa M. Force reports funding from the Bill and Melinda Gates Foundation, Conquer Cancer Foundation, St. Jude Children's Research Hospital and the NIH Loan Repayment Program; these are disclosed for transparency and not believed to bias her contributions to this work. Other authors declare no potential conflicts of interest. The study was funded by the World Health Organisation and the National Health and Medical Research Council of Australia (Canfell NHMRC Leadership Fellowship APP1194679). The funders had no role in the design, conduct and submission of the study, or in the decision to submit the article for publication. While AI and FR are employees of the World Health Organisation, they are involved in our study as individual authors, and this work represents their own views Ver menos

Abstract: While previous reviews found a positive association between pre-existing cancer diagnosis and COVID-19-related death, most early studies did not distinguish long-term cancer survivors from those recently diagnosed/treated, nor adjust for important confounders including age. We aimed to consolidate higher-quality evidence on risk of COVID-19-related death for people with recent/active cancer (compared to people without) in the pre-COVID-19-vaccination period. We searched the WHO COVID-19 Global Research Database (20 December 2021), and Medline and Embase (10 May 2023). We included studies adjusting for age and sex, and providing details of cancer status. Risk-of-bias assessment was based on the Newcastle-Ottawa Scale. Pooled adjusted odds or risk ratios (aORs, aRRs) or hazard ratios (aHRs) and 95% confidence intervals (95% CIs) were calculated using generic inverse-variance random-effects models. Random-effects meta-regressions were used to assess associations between effect estimates and time since cancer diagnosis/treatment. Of 23?773 unique title/abstract records, 39 studies were eligible for inclusion (2 low, 17 moderate, 20 high risk of bias). Risk of COVID-19-related death was higher for people with active or recently diagnosed/treated cancer (general population: aOR?=?1.48, 95% CI: 1.36-1.61, I2 ?=?0; people with COVID-19: aOR?=?1.58, 95% CI: 1.41-1.77, I2 ?=?0.58; inpatients with COVID-19: aOR?=?1.66, 95% CI: 1.34-2.06, I2 ?=?0.98). Risks were more elevated for lung (general population: aOR?=?3.4, 95% CI: 2.4-4.7) and hematological cancers (general population: aOR?=?2.13, 95% CI: 1.68-2.68, I2 ?=?0.43), and for metastatic cancers. Meta-regression suggested risk of COVID-19-related death decreased with time since diagnosis/treatment, for example, for any/solid cancers, fitted aOR?=?1.55 (95% CI: 1.37-1.75) at 1?year and aOR?=?0.98 (95% CI: 0.80-1.20) at 5?years post-cancer diagnosis/treatment. In conclusion, before COVID-19-vaccination, risk of COVID-19-related death was higher for people with recent cancer, with risk depending on cancer type and time since diagnosis/treatment Ver menos